| Status: AWMSG assessment in progress | |
For the off-label neoadjuvant treatment of adult patients with previously untreated resectable stage II or III deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) colon adenocarcinoma |
|
Medicine details |
|
| Medicine name | nivolumab (Opdivo®) + ipilimumab (Yervoy®) |
| Formulation | intravenous infusion |
| Reference number | 7882 |
| Indication | As above |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | One Wales |
| Status | AWMSG assessment in progress |
| Scrutiny Panel meeting date | 04/06/2026 |
| OWMAG meeting date | 02/11/2026 |
| AWMSG meeting date | 02/12/2026 |